In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after ...
Cell free RNA diagnostics market is projected to reach US$ 204.5 Mn by 2035, expanding at a CAGR of 14.5% from 2025 to 2035 ...
Some younger patients with B-cell acute lymphoblastic leukemia may be able to avoid total body irradiation conditioning prior ...
The Global Targeted Sequencing Market is poised for growth due to rising demand for precise diagnostics in genetic disorders ...
According to Brad Schweigert, PXG Chief Operating Officer, "Frequency tuning, structural reinforcement, and advanced MOI engineering allowed us to create metalwoods that are objectively faster and ...
From enzymes and lipid nanoparticles to large-scale process design, four global innovators redefine RNA-based medicine development and delivery.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ...
Avance Biosciences has opened a 75,000-square-foot biomanufacturing facility in Northwest Houston. The facility will support ...
The National Organization for Rare Disorders (NORD®) has designated UC Davis Health as a NORD Rare Disease Center of ...
Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical ...
Spatial RNA medicine combines transcriptomics and RNA therapeutics, mapping gene expression in tissues to enhance precision ...
Disease development is often shaped by genetics, with how much or how little a gene is expressed influencing disease risk. While advances in technology and sequencing methods have led to a greater ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback